Article
Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study.
Cancer communications (London, England) - 22 May 2018
Zhang Shirong, Zhu Lucheng, Xia Bing, Chen Enguo, Zhao Qiong, Zhang Xiaochen, Chen Xueqin, Chen Xufeng, Ma Shenglin
Abstract excerpt
INTRODUCTION: Plasma circulating tumor DNA (ctDNA) is an ideal approach to detecting the epidermal growth factor receptor (EGFR) T790M mutation, which is a major mechanism of resistance to first-generation EGFR-tyrosine kinase inhibitor (TKI) therapy. The present study aimed to explore the association of ctDNA-identified T790M mutation with disease failure sites and clinical prognosis in non-small cell lung...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.